Staging non-small cell lung cancer with whole-body PET

Radiology

Volumn 212, Issue 3, 1999, Pages 803-809

  Marom, Edith M ^a   McAdams, H Page ^a   Erasmus, Jeremy J ^a   Goodman, Philip C ^a   Culhane, Donna K ^b   Coleman, R Edward ^a   Herndon, James E ^a   Patz Jr , Edward F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Bronchi, neoplasms; Lung neoplasms, emission CT (ECT); Lung neoplasms, staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BONE SCINTISCANNING; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 0032843025     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.212.3.r99se21803     Document Type: Article

References (36)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998; 48:6-29.
2. Bragg DG. Current applications of imaging procedures in the patient with lung cancer. Int J Radiat Oncol Biol Phys 1991; 21:847-885.
3. Steinert H, et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 1997; 202:441-446.
4. Bury T, Dowalti A, Paulus P, et al. Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. Eur Respir J 1997; 10:2529-2534.
5. Valk PE, Pounds TR, Hopkins DM, et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 1995; 60:1573-1582.
6. 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 1994; 344:1265-1266.
7. Larcos G, Maisey MN. FDG-PET screening for cerebral metastases in patients with suspected malignancy. Nucl Med Commun 1996; 17:197-198.
8. Lowe VJ, Fletcher JW, Gobar L, et al. Prospective investigation of PET in lung nodules (PIOPILN). J Clin Oncol 1998; 16:1075-1084.
9. DeGrado TR, Turkington TG, Williams JJ, Stearns CW, Hoffman JM, Coleman RE. Performance characteristics of a whole-body PET scanner. J Nucl Med 1994; 35: 1398-1406.
10. Coleman RE, Hoffman JM, Hanson MW, Sostman HD, Schold SC. Clinical application of PET for the evaluation of brain tumors. J Nucl Med 1991; 32:616-622.
11. Patz EF, Lowe VJ, Hoffman JM, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993; 188:487-490.
12. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111:1710-1717.
13. Patz Jr EF, Erasmus JJ, McAdams HP, et al. Lung cancer staging and management: comparison of contrast-enhanced and nonenhanced helical CT of the thorax. Radiology 1999; 212:56-60.
14. Korobkin M, Brodeur FJ, Yutzy GG, et al. Differentiation of adrenal adenomas from nonadenomas using CT attenuation values. AJR 1996; 166:531-536.
15. Gdeedo A, Van Schill P, Corthouts B, Van Mieghem F, Van Meerbeek J, Van Mark E. Prospective evaluation of computed tomography and mediastinoscopy in mediastinal lymph node staging. Eur Respir J 1997; 10:1547-1551.
16. Lee JD, Ginsberg RJ. Lung cancer staging: the value of ipsilateral scalene lymph node biopsy performed at mediastinoscopy. Ann Thorac Surg 1996; 62:338-341.
17. Nakanishi R, Yasumoto K. Combined thoracoscopy and mediastinoscopy for mediastinal lymph node staging of lung cancer. Int Surg 1996; 81:359-361.
18. Salvatierra A, Baamonde C, Llamas JM, Cruz F, Lopez-Pujol J. Extrathoracic staging of bronchogenic carcinoma. Chest 1990; 97:1052-1058.
19. Quinn DL, Ostrow LB, Porter DK, Shelton DK Jr, Jackson DE Jr. Staging of non-small cell bronchogenic carcinoma. Chest 1986; 89:270-275.
20. Reinig JW, Doppman JL, Dwyer AJ, Johnson AR, Knop RH. Adrenal masses differentiated by MR. Radiology 1986; 158:81-84.
21. Oliver TW Jr, Bernardino ME, Miller JI, Mansour K, Greene D, Davis WA. Isolated adrenal masses in nonsmall-cell bronchogenic carcinoma. Radiology 1984; 153: 217-218.
22. Mody MK, Kazerooni EA, Korobkin M. Percutaneous CT-guided biopsy of adrenal masses: immediate and delayed complications. J Comput Assist Tomogr 1995; 19:434-439.
23. Caldironi MW, Boccato P, Maifredini CS, et al. Cyto-assisted, ultrasound-guided biopsy in the diagnosis of focal disease of the abdomen. Tumori 1991; 77:65-69.
24. Jaeger HJ, MacFie J, Mitchel CJ, Couse N, Wai D. Diagnosis of abdominal masses with percutaneous biopsy guided by ultrasound. BMJ 1990; 301:1188-1191.
25. vanSonnenberg E, Wittenberg J, Ferruci JT Jr, Mueller PR, Simone JF. Triangulation method for percutaneous needle guidance: the angled approach to upper abdominal masses. AJR 1981; 137:757-761.
26. Bernardino ME, Walther MM, Phillips VM, et al. CT-guided adrenal biopsy: accuracy, safety, and indications. AJR 1985; 144: 67-69.
27. Erasmus JJ, Patz EF, McAdams HP, et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma by using 18F-fluorodeoxyglucose positron emission tomography. AJR 1997; 168:1357-1360.
28. Tarver RD, Richmond BD, Klatte EC. Cerebral metastases from lung carcinoma: neurological and CT correlation. Radiology 1984; 153:689-692.
29. Yokoi K, Miyazawa N, Arai T. Brain metastasis in resected lung cancer: value of intensive follow-up with computed tomography. Ann Thorac Surg 1996; 61:546-551.
30. Hustinx R, Paulus P, Jacquet N, Jerusalem G, Bury T, Rigo P. Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases. Ann Oncol 1998; 9:397-401.
31. Abdel-Nabi H, Doerr RJ, Lamonica DM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998; 206:755-560.
32. Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK, Pinson CW. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998; 133:510-515.
33. Schiepers C, Penninckx F, De Vadder N, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995; 21:517-522.
34. Ogunblyi OA, Flanagan FL, Dehdashti F, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997; 4:613-620.
35. Valk PE, Pounds TR, Tesa RD, Hopkins DM, Haseman MK. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol 1996; 23:737-743.
36. Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med 1996; 37:1428-1436.